| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.20(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
136,870 |
194,989 |
260,525 |
524,601 |
| Total Sell Value |
$2,679,704 |
$3,814,194 |
$5,546,549 |
$13,449,119 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
19 |
38 |
75 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cole Douglas G. |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
5,327 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
2,544,370 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
136,163 |
|
- |
|
| Flatley Jay T |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,074 |
330,327 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,253 |
3,253 |
|
- |
|
| Flatley Jay T |
Director |
– • – |
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
I/I |
3,253 |
328,253 |
|
- |
|
| Klein Peter S |
Director |
– • – |
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,253 |
3,253 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,253 |
3,253 |
|
- |
|
| Cole Douglas G. |
Director |
– • – |
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,253 |
3,253 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2021-06-01 |
4 |
AS |
$60.98 |
$1,125,648 |
I/I |
(18,333) |
2,210,742 |
|
-15% |
|
| Nelsen Robert |
Director |
– • – |
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,253 |
10,358 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2021-05-26 |
4 |
AS |
$64.90 |
$108,911 |
D/D |
(1,666) |
134,089 |
|
-22% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2021-05-24 |
4 |
AS |
$60.03 |
$528,580 |
D/D |
(8,806) |
2,542,296 |
|
-21% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2021-05-21 |
4 |
AS |
$60.13 |
$2,282,468 |
D/D |
(37,957) |
2,551,102 |
|
-14% |
|
| Nelsen Robert |
Director |
– • – |
2021-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,537 |
7,105 |
|
- |
|
| Nelsen Robert |
Director |
– • – |
2021-05-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(500,000) |
9,668,749 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2021-05-04 |
4 |
AS |
$55.09 |
$554,864 |
I/I |
(10,000) |
511,582 |
|
-6% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2021-05-03 |
4 |
AS |
$60.08 |
$194,589 |
D/D |
(3,237) |
2,589,059 |
|
-11% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2021-05-03 |
4 |
AS |
$58.45 |
$1,075,102 |
I/I |
(18,333) |
2,229,075 |
|
-11% |
|
| Sato Vicki L |
Director |
– • – |
2021-04-28 |
4 |
AS |
$60.71 |
$103,538 |
D/D |
(1,666) |
135,755 |
|
-15% |
|
| Sato Vicki L |
Director |
– • – |
2021-03-31 |
4 |
AS |
$54.38 |
$93,992 |
D/D |
(1,666) |
137,421 |
|
-6% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2021-03-29 |
4 |
AS |
$54.62 |
$154,126 |
I/I |
(2,822) |
162,319 |
|
-3% |
|
| Nelsen Robert |
Director |
– • – |
2021-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,538 |
4,568 |
|
- |
|
| Nelsen Robert |
Director |
– • – |
2021-03-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(500,000) |
10,168,749 |
|
- |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2021-03-15 |
4 |
AS |
$61.16 |
$3,094,563 |
I/I |
(50,000) |
850,000 |
|
3% |
|
416 Records found
|
|
Page 8 of 17 |
|
|
0.36 (1.93%) 
